LPL Financial LLC Buys 129,313 Shares of Abrdn Life Sciences Investors (NYSE:HQL)

LPL Financial LLC grew its stake in shares of Abrdn Life Sciences Investors (NYSE:HQL) by 82.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 287,095 shares of the company’s stock after acquiring an additional 129,313 shares during the period. LPL Financial LLC owned about 1.05% of Abrdn Life Sciences Investors worth $3,767,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HQL. BankPlus Trust Department purchased a new stake in shares of Abrdn Life Sciences Investors in the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC raised its holdings in shares of Abrdn Life Sciences Investors by 379.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock valued at $64,000 after acquiring an additional 3,847 shares in the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in Abrdn Life Sciences Investors in the fourth quarter worth about $160,000. Sanctuary Advisors LLC grew its holdings in Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after acquiring an additional 1,355 shares in the last quarter. Finally, Kapstone Financial Advisors LLC increased its position in Abrdn Life Sciences Investors by 11.0% during the 4th quarter. Kapstone Financial Advisors LLC now owns 13,123 shares of the company’s stock valued at $185,000 after purchasing an additional 1,300 shares during the period. Hedge funds and other institutional investors own 32.21% of the company’s stock.

Insiders Place Their Bets

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $11.57, for a total value of $79,705.73. Following the transaction, the insider now owns 3,124,472 shares in the company, valued at $36,150,141.04. The trade was a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 225,922 shares of company stock worth $2,988,660 over the last 90 days. Company insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Stock Performance

NYSE:HQL opened at $11.10 on Friday. The firm has a 50-day simple moving average of $13.06 and a 200-day simple moving average of $13.83. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 16.94%. The ex-dividend date was Friday, February 21st.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.